BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC trimmed its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 20.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 496,812 shares of the biotechnology company’s stock after selling 129,093 shares during the quarter. Voya Investment Management LLC owned about 0.24% of BioCryst Pharmaceuticals worth $3,726,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter worth $32,000. GF Fund Management CO. LTD. acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter worth about $33,000. GAMMA Investing LLC lifted its holdings in BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,449 shares during the period. New Age Alpha Advisors LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $62,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $79,000. Institutional investors own 85.88% of the company’s stock.

Insider Activity

In related news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $7.70 on Friday. The firm has a 50 day simple moving average of $8.32 and a 200 day simple moving average of $8.70. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.01 and a 52 week high of $11.31. The stock has a market cap of $1.62 billion, a P/E ratio of -42.78, a P/E/G ratio of 1.60 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. The firm’s quarterly revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.06) EPS. Sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BCRX. Wedbush upped their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research note on Monday, June 30th. Needham & Company LLC restated a “buy” rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Bank of America increased their price target on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, July 1st. Royal Bank Of Canada reissued an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Finally, Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $16.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.